---
document_datetime: 2026-02-10 15:50:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vueway.html
document_name: vueway.html
version: success
processing_time: 0.0717328
conversion_datetime: 2026-02-13 18:46:26.277733
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.2
  docling: 2.73.1
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Search

- [Medicines](/en/medicines)
    - [Find medicine](/en/medicines)
    - [Therapeutic areas: latest updates](/en/medicines/therapeutic-areas-latest-updates)
    - [Download medicine data](/en/medicines/download-medicine-data)
    - [What we publish on medicines and when](/en/medicines/what-we-publish-medicines-when)
    - [Medicines under evaluation](/en/medicines/medicines-human-use-under-evaluation)
    - [National registers](/en/medicines/national-registers-authorised-medicines)
- [Human regulatory](/en/human-regulatory-overview)
    - [Overview](/en/human-regulatory-overview)
    - [Research and development](/en/human-regulatory-overview/research-development)
    - [Marketing authorisation](/en/human-regulatory-overview/marketing-authorisation)
    - [Post-authorisation](/en/human-regulatory-overview/post-authorisation)
    - [Medical devices](/en/human-regulatory-overview/medical-devices)
    - [Herbal products](/en/human-regulatory-overview/herbal-medicinal-products)
- [Veterinary regulatory](/en/veterinary-regulatory-overview)
    - [Overview](/en/veterinary-regulatory-overview)
    - [Research and development](/en/veterinary-regulatory-overview/research-development-veterinary-medicines)
    - [Marketing authorisation](/en/veterinary-regulatory-overview/marketing-authorisation-veterinary-medicines)
    - [Post-authorisation](/en/veterinary-regulatory-overview/post-authorisation-veterinary-medicines)
- [Committees](/en/committees)
    - [Overview](/en/committees)
    - [How the committees work](/en/committees/how-committees-work)
    - [CHMP](/en/committees/committee-medicinal-products-human-use-chmp)
    - [CVMP](/en/committees/committee-veterinary-medicinal-products-cvmp)
    - [PRAC](/en/committees/pharmacovigilance-risk-assessment-committee-prac)
    - [COMP](/en/committees/committee-orphan-medicinal-products-comp)
    - [HMPC](/en/committees/committee-herbal-medicinal-products-hmpc)
    - [CAT](/en/committees/committee-advanced-therapies-cat)
    - [PDCO](/en/committees/paediatric-committee-pdco)
    - [Working parties and other groups](/en/committees/working-parties-other-groups)
- [News &amp; events](/en/news-events)
    - [Overview](/en/news-events)
    - [News](/en/news)
    - [Events](/en/events/upcoming-events)
    - [What's new](/en/news-events/whats-new)
    - [Committee highlights](/en/news-events/committee-highlights)
    - [Publications](/en/news-and-events/publications)
    - [Press and social media](/en/news-events/press-social-media)
    - [Podcast: Inside EMA](/en/news-events/podcast-inside-ema)
    - [Open consultations](/en/news-events/open-consultations)
    - [RSS feeds](/en/news-events/rss-feeds)
- [Partners &amp; networks](/en/partners-networks)
    - [Overview](/en/partners-networks)
    - [EU partners](/en/partners-networks/eu-partners)
    - [International activities](/en/partners-networks/international-activities)
    - [Patients and consumers](/en/partners-networks/patients-consumers)
    - [Healthcare professionals](/en/partners-networks/healthcare-professionals)
    - [Academia](/en/partners-networks/academia)
    - [Pharmaceutical industry](/en/partners-networks/pharmaceutical-industry)
    - [Networks](/en/partners-networks/networks)
    - [Health technology assessment bodies](/en/partners-networks/health-technology-assessment-bodies)
    - [One Health approach](/en/partners-networks/one-health-approach)
    - [Animal health practitioners](/en/partners-networks/animal-health-practitioners)
    - [One substance - one assessment](/en/partners-networks/one-substance-one-assessment-osoa-eu-collaboration-chemicals-related-data)
- [About us](/en/about-us)
    - [Overview](/en/about-us)
    - [What we do](/en/about-us/what-we-do)
    - [Who we are](/en/about-us/who-we-are)
    - [How we work](/en/about-us/how-we-work)
    - [Fees](/en/about-us/fees-payable-european-medicines-agency)
    - [Support to SMEs](/en/about-us/support-smes)
    - [Annual reports and work programmes](/en/about-us/annual-reports-work-programmes)
    - [History of EMA](/en/about-us/history-ema)
    - [Careers](/en/about-us/careers)
    - [Procurement](/en/about-us/procurement-grants)
    - [Glossaries](/en/about-us/glossaries)
    - [About this website](/en/about-us/about-website)
    - [Data protection and privacy](/en/about-us/data-protection-privacy-ema)
    - [Contacts](/en/about-us/contacts-european-medicines-agency)

1. [Home](/en/homepage)
2. [Medicines](https://www.ema.europa.eu/en/medicines)
3. Vueway

# Vueway

[RSS](/en/individual-human-medicine.xml/77413)

##### Authorised

This medicine is authorised for use in the European Union

gadopiclenol Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vueway](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vueway is a contrast agent, a medicine used to improve the contrast of images obtained during magnetic resonance imaging (MRI) examinations. This helps doctors find certain pathologies in patients in whom this would not be possible otherwise. Vueway is used in adults and children from birth.

Vueway contains the active substance gadopiclenol.

Expand section

Collapse section

## How is Vueway used?

Vueway is given as an injection into a vein by a specialised healthcare professional, just before the MRI scan. It can only be obtained with a prescription.

For more information about using Vueway, see the package leaflet or contact your doctor or pharmacist.

## How does Vueway work?

The active substance in Vueway, gadopiclenol, contains gadolinium, a rare-earth metal element used in contrast agents to help obtain better MRI images. MRI is an imaging method that relies on the tiny magnetic fields produced by water molecules in the body. Once injected, gadolinium interacts with the water molecules. As a result of this interaction, the water molecules give a stronger signal in the locations reached by the contrast agent, and this helps to obtain a brighter picture.

## What benefits of Vueway have been shown in studies?

Two main studies were carried out to investigate whether MRI images made with Vueway were comparable to those made with another contrast agent, and better than those made without a contrast agent. One study involved 256 adults who had, or were highly suspected to have, a tumour in their brain or spinal cord, based on the outcome of a previous imaging procedure (such as an MRI or CT scan). The second study involved 304 adults with a tumour or other pathological tissue (such as a cyst) in another part of their body.

Study participants had MRI scans in combination with Vueway, in combination with another gadolinium-based contrast agent and without a contrast agent. Doctors experienced in analysing MRI images then compared how clearly the tumours or pathologies were visible in the different scans. All doctors considered that MRI images with Vueway were clearer than those made without a contrast agent, and comparable with those made with the other contrast agent.

Two additional studies were undertaken in children. The first involved 80 children aged from 2 to less than 18 years and the second involved 36 children aged less than 2 years. The studies did not compare gadopiclenol with another contrast agent. Each child first had MRI images taken without any contrast agent, followed by MRI images taken with gadopiclenol. The results showed that gadopiclenol made MRI images clearer and helped doctors make more confident diagnoses. Data also showed that Vueway behaves in a similar way in children as it does in adults.

## What are the risks associated with Vueway?

For the full list of side effects and restrictions with Vueway, see the package leaflet.

The most common side effects with Vueway (which may affect up to 1 in 10 people) include headache and injection site reactions such as pain and coldness. Other common side effects (which may affect up to 1 in 100 people) include nausea, fatigue and diarrhoea.

## Why is Vueway authorised in the EU?

Using Vueway as a contrast agent improved the quality of MRI scans compared to an unenhanced scans. The safety profile of Vueway is in line with that of other gadolinium-based contrast agents. Importantly, Vueway contains gadolinium in a specific complex. This means that it can be given at half the dose of gadolinium compared with other, non-specific gadolinium-containing contrast agents while providing the same contrast enhancement. The European Medicines Agency therefore decided that Vueway's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vueway?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vueway have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vueway are continuously monitored. Suspected side effects reported with Vueway are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vueway

Vueway received a marketing authorisation valid throughout the EU on 07 December 2023.

Vueway : EPAR - Medicine overview

Reference Number: EMADOC-1829012207-40105

English (EN) (121.07 KB - PDF)

**First published:** 13/02/2024

**Last updated:** 10/02/2026

[View](/en/documents/overview/vueway-epar-medicine-overview_en.pdf)

Vueway : EPAR - Risk management plan

English (EN) (11.38 MB - PDF)

**First published:** 13/02/2024

**Last updated:** 10/02/2026

[View](/en/documents/rmp/vueway-epar-risk-management-plan_en.pdf)

## Product information

Vueway : EPAR - Product information

English (EN) (506.54 KB - PDF)

**First published:** 13/02/2024

**Last updated:** 10/02/2026

[View](/en/documents/product-information/vueway-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-387)

български (BG) (593.65 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/bg/documents/product-information/vueway-epar-product-information_bg.pdf)

español (ES) (510.97 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/es/documents/product-information/vueway-epar-product-information_es.pdf)

čeština (CS) (543.3 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/cs/documents/product-information/vueway-epar-product-information_cs.pdf)

dansk (DA) (522.66 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/da/documents/product-information/vueway-epar-product-information_da.pdf)

Deutsch (DE) (508.75 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/de/documents/product-information/vueway-epar-product-information_de.pdf)

eesti keel (ET) (517.78 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/et/documents/product-information/vueway-epar-product-information_et.pdf)

ελληνικά (EL) (585.29 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/el/documents/product-information/vueway-epar-product-information_el.pdf)

français (FR) (504.6 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/fr/documents/product-information/vueway-epar-product-information_fr.pdf)

hrvatski (HR) (574.32 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/hr/documents/product-information/vueway-epar-product-information_hr.pdf)

íslenska (IS) (432.46 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/is/documents/product-information/vueway-epar-product-information_is.pdf)

italiano (IT) (429.01 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/it/documents/product-information/vueway-epar-product-information_it.pdf)

latviešu valoda (LV) (528.92 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/lv/documents/product-information/vueway-epar-product-information_lv.pdf)

lietuvių kalba (LT) (505.5 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/lt/documents/product-information/vueway-epar-product-information_lt.pdf)

magyar (HU) (501.68 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/hu/documents/product-information/vueway-epar-product-information_hu.pdf)

Malti (MT) (581.3 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/mt/documents/product-information/vueway-epar-product-information_mt.pdf)

Nederlands (NL) (502.95 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/nl/documents/product-information/vueway-epar-product-information_nl.pdf)

norsk (NO) (480.3 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/no/documents/product-information/vueway-epar-product-information_no.pdf)

polski (PL) (598.53 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/pl/documents/product-information/vueway-epar-product-information_pl.pdf)

português (PT) (442.77 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/pt/documents/product-information/vueway-epar-product-information_pt.pdf)

română (RO) (567.09 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/ro/documents/product-information/vueway-epar-product-information_ro.pdf)

slovenčina (SK) (569 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/sk/documents/product-information/vueway-epar-product-information_sk.pdf)

slovenščina (SL) (574.37 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/sl/documents/product-information/vueway-epar-product-information_sl.pdf)

Suomi (FI) (490.35 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/fi/documents/product-information/vueway-epar-product-information_fi.pdf)

svenska (SV) (534.01 KB - PDF)

**First published:**

13/02/2024

**Last updated:**

10/02/2026

[View](/sv/documents/product-information/vueway-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000249008 22/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vueway : EPAR - All authorised presentations

English (EN) (99.41 KB - PDF)

**First published:** 13/02/2024

[View](/en/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-98)

български (BG) (121.49 KB - PDF)

**First published:**

13/02/2024

[View](/bg/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_bg.pdf)

español (ES) (70.78 KB - PDF)

**First published:**

13/02/2024

[View](/es/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_es.pdf)

čeština (CS) (105.57 KB - PDF)

**First published:**

13/02/2024

[View](/cs/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (106.34 KB - PDF)

**First published:**

13/02/2024

[View](/da/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (91.04 KB - PDF)

**First published:**

13/02/2024

[View](/de/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (96.28 KB - PDF)

**First published:**

13/02/2024

[View](/et/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (111.08 KB - PDF)

**First published:**

13/02/2024

[View](/el/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_el.pdf)

français (FR) (88.36 KB - PDF)

**First published:**

13/02/2024

[View](/fr/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (162.42 KB - PDF)

**First published:**

13/02/2024

[View](/hr/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (96.14 KB - PDF)

**First published:**

13/02/2024

[View](/is/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_is.pdf)

italiano (IT) (68.2 KB - PDF)

**First published:**

13/02/2024

[View](/it/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (103.46 KB - PDF)

**First published:**

13/02/2024

[View](/lv/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (123.58 KB - PDF)

**First published:**

13/02/2024

[View](/lt/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (127.58 KB - PDF)

**First published:**

13/02/2024

[View](/hu/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (130.11 KB - PDF)

**First published:**

13/02/2024

[View](/mt/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (87.01 KB - PDF)

**First published:**

13/02/2024

[View](/nl/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (69.13 KB - PDF)

**First published:**

13/02/2024

[View](/no/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_no.pdf)

polski (PL) (128.3 KB - PDF)

**First published:**

13/02/2024

[View](/pl/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_pl.pdf)

português (PT) (88.47 KB - PDF)

**First published:**

13/02/2024

[View](/pt/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_pt.pdf)

română (RO) (92.93 KB - PDF)

**First published:**

13/02/2024

[View](/ro/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (110.85 KB - PDF)

**First published:**

13/02/2024

[View](/sk/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (86.54 KB - PDF)

**First published:**

13/02/2024

[View](/sl/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (99.27 KB - PDF)

**First published:**

13/02/2024

[View](/fi/documents/all-authorised-presentations/vueway-epar-all-authorised-presentations_fi.pdf)

## Product details

Name of medicine Vueway Active substance Gadopiclenol International non-proprietary name (INN) or common name gadopiclenol Therapeutic area (MeSH) Magnetic Resonance Imaging Anatomical therapeutic chemical (ATC) code V08CA12

### Pharmacotherapeutic group

Paramagnetic contrast media

### Therapeutic indication

This medicinal product is for diagnostic use only. Vueway is indicated in adults and children from birth for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualization of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of: - the brain, spine, and associated tissues of the central nervous system (CNS); - the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system. It should be used only when diagnostic information is essential and not available with unenhanced MRI.

## Authorisation details

EMA product number EMEA/H/C/006172

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Bracco Imaging S.p.A.

Via Egidio Folli 50

Opinion adopted 12/10/2023 Marketing authorisation issued 07/12/2023 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vueway : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (155.05 KB - PDF)

**First published:** 20/10/2025

**Last updated:** 10/02/2026

[View](/en/documents/procedural-steps-after/vueway-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vueway : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (149.45 KB - PDF)

**First published:** 21/08/2024

**Last updated:** 20/10/2025

[View](/en/documents/procedural-steps-after/vueway-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Vueway-VR-0000249008  : EPAR - Assessment report - Variation

Adopted

Reference Number: EMADOC-1700519818-2671004

English (EN) (2.84 MB - PDF)

**First published:** 10/02/2026

[View](/en/documents/variation-report/vueway-vr-0000249008-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Vueway (EMAVR0000249008)

Adopted

Reference Number: EMADOC-1700519818-2707211

English (EN) (134.81 KB - PDF)

**First published:** 12/12/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vueway-emavr0000249008_en.pdf)

Vueway-H-C-PSUSA-00000232-202403 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/42286/2025

English (EN) (161.87 KB - PDF)

**First published:** 04/02/2025

[View](/en/documents/scientific-conclusion/vueway-h-c-psusa-00000232-202403-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Vueway : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/577756/2023

English (EN) (10.02 MB - PDF)

**First published:** 13/02/2024

[View](/en/documents/assessment-report/vueway-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vueway

Adopted

Reference Number: EMA/CHMP/448534/2023

English (EN) (152.97 KB - PDF)

**First published:** 13/10/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vueway_en.pdf)

#### News on Vueway

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 December 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-december-2025) 12/12/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2023) 13/10/2023

**This page was last updated on** 10/02/2026

## Share this page

[Back to top](#main-content)